

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Staphylococcus aureus and Dairy Udder

Amjad Islam Aqib, Muhammad Ijaz, Muhammad Shoaib, Iqra Muzammil, Hafiz Iftikhar Hussain, Tean Zaheer, Rais Ahmed, Iqra Sarwar, Yasir Razzaq Khan and Muhammad Aamir Naseer

Abstract

Staphylococcus aureus is a major causative agent of intra-mammary infections in dairy animals with potential virulence of surface components, toxins, and extracellular enzymes. About 74% quarter prevalence of *S. aureus* in bovine udder with overall prevalence exceeding 61% in dairy animals. About 17 different serotypes of dairy originated *S. aureus* have been reported with 24 virulence coding genes for leukocidins (lukED/lukM), pyrogenic toxin super antigen (PTSAg), haemolysins (hla-hlg), toxic-shock syndrome toxin (tst), enterotoxins (sea-seo, seu), exfoliative toxins (eta, etb), and genes for methicillin (mecA) and penicillin (blaZ) resistance. Attainment of refuge inside the macrophages and neutrophils is a major cause of *S. aureus* mastitis persistence. Mammary prebiotics and probiotics are recently being used as alternatives to antibiotic for the prevention of mastitis. Literature showed anti-staphylococcus vaccines with different results depending upon types of immunization, route of administration and adjuvant used. Studies have shown that herd specific as well as commercial *S. aureus* vaccines reduce new infections in dairy animals. Experiments are still in progress for the use of vaccines against *S. aureus* mastitis with optimal efficacy and reliability. Perhaps, there might be bright future because of highly satisfactory trial results of mastitis vaccines in the lab animals.

Keywords: *S. aureus*, dairy udder, transmission, pathogenesis, economic impacts, treatment, prevention

1. Introduction

Staphylococcus aureus is a symbiotic and opportunistic microorganism that can colonize various sites of different animals and humans. This bacteria can cause serious infections in humans and animals [1]. In animals, bovine mastitis, commonly caused by various bacteria, is one of the most devastating disease in dairy farming worldwide. Of these bacteria, *Staphylococcus aureus* is the leading pathogen causing the most dangerous mastitis in cattle and the most difficult dairy product in most countries. *Staphylococcus aureus* has emerged as superbug of dairy udder, compromising animal health and economy [2]. Its virulence is due to its

ability of producing wide array of virulence factors that enhances its attachment, colonization, longer persistence and escaping the immune response. Such resistant strains are distinguished by systemic heterogeneity, genetic variety, interactions between complex community and the extracellular matrix of macromolecular substances [3].

Staphylococcus aureus has a variety of strains, most notably multi-drug resistance and biofilm formation. The latter has received a lot of attention due to its ability to minimize the effects of antibiotics, colonize the mucous membrane of the epithelium, last longer, avoid immune reactions, and contribute to etiology [4]. Methicillin resistant *S. aureus* strains have been designated as emerging pathogen in livestock and dairy animals. Hospital acquired MRSA and community associated MRSA are limited to humans only, but livestock occupational personals may have infections with human originated MRSA [5].

The successful mastitis therapy depends on various factors such as accurate diagnosis, elimination of causative agent, stage of disease, severity of the infection, selection of the drugs, route of drugs administration along with other supportive treatments [6, 7] and some other factors regarding mastitis causing organisms. However, irrespective of the appropriate use of antibiotic, the mastitis may not be treated successfully [8]. The treatment failure mainly occurs due to insufficient contact of antimicrobials and disease-causing microorganisms in the udder. Mastitis can incur economic losses in both ways either directly and indirectly [9]. The direct losses include veterinary expenditure, labor costs, reduced production, poor quality milk and discarded milk. Whereas, the indirect losses are not obvious to the producers and are termed as “hidden losses” which include increased risk of other diseases, poor fertility rate, increased culling rate and sometime mortality. So, total cost can be much more than the direct losses [10–12]. This chapter addresses the following aspects such as transmission, pathogenesis, strains spectrum, economic impact, emerging treatment and prevention strategies to control *S. aureus* dairy udder infection.

2. Transmission of *Staphylococcus aureus* in udder infections

The main reservoirs of *Staphylococcus aureus* are infected mammary glands, ducts, and papillary lesions. However, this bacteria also found on the skin, nose and teat passages. The bacteria spread to uninfected areas through the lining of the teat cups, milker's hands, towels and fruit flies. *Staphylococcus aureus* does not persist on healthy teat skin, but tends to colonize damaged skin and teat lesions. The body reproduces the infected lesion, increasing the likelihood of teat colonization and subsequent udder infection. Heifers infected during calf pregnancy are an important reservoir that can be passed on to uninfected *Staphylococcus aureus* herds. There has been much controversy over the route of infection with *Staphylococcus aureus* in early prenatal heifers, but it is possible that the cause is a calf that was fed on a mother infected with *Staphylococcus aureus*. Data is limited, but if you have a problem with *Staphylococcus aureus* on your farm, you should definitely consider choosing scrapes carefully (such as cryo-sterilization). Obviously, a good treatment plan for mastitis will take into account the absence of this disease in heifers [13].

3. Pathogenesis of *S. aureus* in udder infection

Bacterial pathogens can recognize, respond and adapt to the harsh environmental conditions that prevail in mammalian hosts during infection. Despite the

host's immune response and antibacterial treatment, it helps to invade, calm, and survive within the host [14]. *Staphylococcus aureus* produces a variety of enzymes, including coagulase, which can coagulate plasma, converting plasma fibrinogen to fibrin, coat bacterial cells, and inhibit nutrition. Hyaluronidase (also called diffusion factor) can break down the hyaluronic acid present in tissues and support the spread of *Staphylococcus aureus* in the host. It also produces DNase (deoxyribonuclease), an enzyme that breaks down DNA. Lipase, which breaks down lipids, and staphylokinase, which breaks down fibrin. It is also known that *Staphylococcus aureus* produces β -lactamase, esterase, elastase and phospholipase for drug resistance, and these enzymes promote colony formation and pathogenicity. Other toxic factors of *Staphylococcus aureus* include leukocidin (which can cause cytolytic destruction of phagocytic cells in some animals) and toxic shock syndrome toxin (TSST). The latter can cause an overproduction of lymphokine, which can lead to tissue damage [15]. Depending on the strain, *Staphylococcus aureus* can release some toxins that are major virulence factors. These toxins act on cell membranes containing superantigens, exfoliating toxins, and some two-component toxins such as alpha toxins, beta toxins, gamma toxins, delta toxins and Panton Valentine's toxins and leukocidin (PVL). It can be divided into three categories, for example toxins [16]. Protein A, which plays an important role in strategies for evading immunity, is immobilized on the staphylococcus-peptide-glycan-pentaglysin bridge using transpeptidase sortase (**Figure 1**). Protein A is able to bind to fragments of the crystal region (Fc) of IgG antibodies (γ -immunoglobulins). This phenomenon is due to the fact that Protein A binds to an IgG antibody produced against the target microorganism and reacts with the corresponding antigen usually present in the patient sample to perform an aggregation test in which a visible aggregation reaction can be observed. The *Staphylococcus aureus* strain is known to produce pigments such as staphyloxanthin and gold carotenoid pigments. These pigment acts primarily as a toxic factor, acting as a bacterial antioxidant and helping microorganisms escape the host's immune system and kill reactive oxygen species used by the pathogen [18]. The toxins produced by *Staphylococcus aureus* destroy the cell membranes and tissues that directly produce milk. White blood cells (leukocytes) are attracted to the area of inflammation and try to fight the infection. First, bacteria damage the tissues lining the teat and mammary gland within 1/4 of a second, eventually leading to scar tissue formation. The bacteria




Figure 1.
Various virulence factors of *S. aureus* [17].

then migrate into the duct system, forming deep-rooted infectious pockets in the lactating (alveolar) cells. The second is the formation of abscesses that prevent their spread, thus avoiding detection by the immune system. Abscesses prevent antibiotics from entering bacteria. This is the main reason for poor response to treatment. However, bacteria can also escape the lethal effects of some antibiotics by hiding in neutrophils (white blood cells) and other host cells preventing exposure to antibiotics. When the white blood cells die (usually within a day or two), the bacteria are released and the infection continues [19].

During infection, the destruction of alveolar and tubular cells reduces the lactation yield. These damaged cells can attach to leukocytes and block the mammary canal that drains the alveolar region, resulting in additional scar tissue, blockage of the canal, and decreased lactation. The teat canal can be opened later, but this usually results in the release of *Staphylococcus aureus* to other areas of the udder. The spread of *Staphylococcus aureus* in the glands leads to the formation of additional abscesses, which can become very large and appear as lumps in the udder (**Figures 2 and 3**). Most cases of *S. aureus* mastitis are asymptomatic, but chronic cows typically have high SCC, abnormal udder tissue, and recurrence of clinical mastitis. Clinically infected areas are usually swollen, milk has visible clots (large clots). Acute infections with *Staphylococcus aureus* usually develops late in lactation. Clinical symptoms such as udder swelling and hardness, milk appearance change) do not appear until the start of the next stage. It is difficult to cure an infection well, because the drug cannot penetrate all foci of infection, and bacteria can avoid contact with antibiotics in the white blood cells. Many strains of *Staphylococcus aureus* have acquired antibiotic resistance (the ability to produce enzymes that




Figure 2. Immune response to *S. aureus* and vice versa inside the mammary gland [20].




Figure 3.
Intracellular invasion of *S. aureus* inside mammary gland [20].

inactivate penicillin and other antibiotics), making treatment impossible. The development of antibiotic resistance during treatment with certain β -lactam antibiotics (such as penicillin) is another reason for treatment failure [20].

4. *Staphylococcus aureus* strains spectrum

Staphylococcus aureus is a major causative agent of intramammary infections in dairy animals with potential virulence of surface components (adhesins, capsular polysaccharides, protein A), toxins, extracellular enzymes and coagulase [21]. About 74% quarter prevalence of *S. aureus* in bovine udder [22] with overall prevalence exceeding 61% in dairy animals [4]. A wide array of genotypic variations has been observed with great genetic diversity in the isolates of bovine as well as caprine origin. Some of the variants are common throughout the globe as ruminant specific *S. aureus* while others are geographic related in the literature [23]. Inflammatory respondent metabolic pathways (BoLA-DRA, GLYCAM1, FCER1G, B2M, CD74, NFKBIA and SDS), milk constituent associated (CSN2 and CSN3) and immunity related (B2M and CD74) are also specific strains of *S. aureus* of dairy mastitis [24, 25].

Staphylococcus aureus genotyping is mostly done by pulsed field gel electrophoresis (PFGE), multi locus sequence typing (MLST), polymerase chain reaction (PCR), *S. aureus* protein A (*spa*) typing, agar typing and typing on the basis of virulence and resistance coding genes [23, 26–31]. Thirty-nine electrophoretic types of *S. aureus* with diverse MLST genotyping had been reported, most of them were showed genetic heterogenicity and classified to one of the eight clonal complexes, suggestive of multiclonal nature of the *S. aureus* isolates from single dairy herd [32]. Clonal 8 complex (i.e., USA300), a lineage known for human infections, has also been isolated from bovine mastitis, suggestive of recent host shift and new adoptive genotypic strain of bovine mastitis [27].

PFGE typing of *S. aureus* from dairy origin showed that PFGE type A was significantly related to teat skin while PFGE type Q was more exclusive to milk and exhibit marked biofilm potential [33]. Overall, PFGE clusters of isolates showed same endotoxin coding genes with indistinguishable banding patterns. Phylogenetic studies based on MLST sequencing classified these clusters into clonal complexes with similar staphylococcal endotoxin genetic profiles [23]. Genotyping of dairy originated *S. aureus* showed five clonal types (PFGE A consisting on sequence type 747 [ST747] and spa type t359; PFGE B with spa type ST750 and t1180; PFGE C with spa type t605 and ST126; PFGE D with spa type t127 and ST751; PFGE F with spa type t002 and ST5). About 63% isolates harbor major clone A but negative for Pantone-Valentine leukocidin and exfoliative toxin D genes [26]. Another reported PFGE typing of dairy originated *S. aureus* revealed 16 PFGE types (from A – P), with M, I and O as most frequent but not significantly variant strains in the field, respectively. PCR typing based on endotoxin genes presence showed that 11.7, 1.8, 2.7, 0.9 and 7.2% isolates carried seb, seb and sec, sec, see, and tsst-1, respectively with zero prevalence of sea and sej genes. PFGE types M and O showed clustering behavior with β -hemolysin and least prevalence of endotoxin coding genes [34].

Staphylococcal protein A types t084, t304 and t688 from subclinical mastitis showed divergent virulence and heterogenicity traits while a novel spa-type t18546 was also reported from dairy udder ailments [35]. Prevalent clonal types of *S. aureus* from bovine udder exhibited generic alterations of epigenetic modulators to surpass immune response of host. The study reported 35,878 transcripts of these strains which differ 23% from reference genomic cluster. Expressive nature of 20,756 transcripts were observed with more than 1 fragment per kilobase of transcript per million mapped fragments and 25.95% of multi-exonic genes alternatively spliced. Alternative Splicing (AS) events for more than 100 immunogenic genes were noted with 379 alternate AS events coding for transcription and splicing proteins. Spa typing of ovine originated *S. aureus* showed 14 diversified clones, most prominent of which were t1773, t967 and t1534 as 62.32, 5.79 and 5.79% respectively. Three novel spa types were also identified with repeats successions (07–23–12–34–12–12–23–03–12–23), (04–31–17–24–25–17–17) and (04–31–17–24–17–17) [36].

Screening of *S. aureus* for endotoxins (SE) showed that >90% isolates were positive for SE genes while 70.1% with exaggerative response. All isolates were positive for biofilm encoding genes (icaA/D, clf/B, can, fnbA). A total of 7 spa types (1 novel spa type t17182), 5 STs, 14 SmaI-pulso-types and 3agr types (no agrII) were reported. PFGE cluster II-CC1-ST1-t127-agr III was the most prevalent clone (56.3%). Isolates of agr III (PFGE Cluster I/II-CC1-ST1-t127/2279) exhibited higher number of virulence genes than other agr types. The MSSA-ST398-t1456-agr I clone showed higher antibiotic resistance, weak biofilm expression and lower level of virulence genes expression [37]. Another study reported agr-I strain harboring penicillin resistance genes while agr-III strains were devoid of that pattern. Antimicrobial resistance encoding genes (tet (L), tet (K), erm (B) and bla (Z)) were frequent in these strains [36]. Thus, the data narrated agr-I and II as different subspecies of dairy originated *S. aureus* [38]. Disruption of the ica operon in a bap-positive *S. aureus* strain showed no alteration in biofilm expression, indicating Bap gene compensatory mechanism for deficit PIA/PNAG product (a biofilm matrix polysaccharide) [39]. 17 different pulsotypes of dairy originated *S. aureus* have been reported with 24 virulence coding genes for leukocidins (lukED/lukM), pyrogenic toxin superantigen (PTSAg), haemolysins (hla-hlg), toxic-shock syndrome toxin (tst), enterotoxins (sea-seo, seu), exfoliative toxins (eta, etb), and genes for methicillin (mecA) and penicillin (blaZ) resistance. PTSAg-encoding genes and plasmid encoded sei, sed and blaZ genes were frequent in persistent intramammary ailments [40].

Staphylococcus aureus classification based on *mecA* gene is narrated as methicillin susceptible (MSSA) and methicillin resistant (MRSA) strains. Studies reported 84% MSSA prevalence with MRSA isolation rate up to 4%. Spa typing of the isolates showed frequent presence of t034 and t529 in MSSA while t121 was noted in MRSA strains. Both types of isolates were positive for endotoxin B, C, D, and E. MLST and PFGE typing of isolates revealed composite genotype profile of ST 5-PFGE USA100-unknown spa type which is of hospital origin and ST 8-PFGE USA300-spa type t121 genotype, commonly designated as community-associated MRSA clone [28]. Another study reported 77.8% MRSA from goat mastitis as strong biofilm producers. Spa typing revealed 44% t127, 33.3% t2049 and 22.2% t7947 type among total MRSA isolates [41].

5. Economic impacts due to *S. aureus* udder infection

Economic impacts of the mastitis are of great financial importance. Mastitis negatively impacts numerous aspects of cow and herd management. Mastitis can incur economic losses in both ways either directly and indirectly [9]. The direct costs include veterinary expenditure, labor costs, reduced production, poor quality milk and discarded milk. Whereas, the indirect losses are not obvious to the producers and are termed as “hidden costs” which include increased risk of other diseases, poor fertility rate, increased culling rate and sometime mortality. So, total cost can be much more than the direct losses [10–12].

A 15–20% of total cow population of the countries having major share in the milk production is affected by mastitis each year. Production losses per effected quarter are estimated 30% of productivity loss whereas, 15% production is lost during entire lactation/cow. The mastitis rate in the heifer can be up to 97% and *S. aureus* has major significance in imparting the huge economic losses. *Staphylococcus aureus* effects animals of various stage and parity e.g. nulliparous, primiparous, primigravid and multiparous [42, 43].

In Holland, the financial losses resulted due to clinical mastitis by Staphylococci were €293/Cow. Whereas, it was €277/cow in every clinical case of mastitis due to staphylococci in first three months after post calving and €168/cow onward for the rest of the lactation. In USA dairy, the annual losses incurred by the mastitis were estimated around \$2billions, while \$400 M in Canada and \$130 M in Australia excluding the antibiotic residue in human diet, expense to preserve the nutritive quality of milk and to prevent milk degradation [12, 44, 45]. There is variation in cost of each component between the herds, partially due to the performance of herd and partially due to difference in preferences of the farmers when the mastitis is detected. Mastitis can impart economic losses to the farmers in following ways.

5.1 Low milk yield

The loss of yield depends on certain factors of great importance like severity of mastitis, nature of causative agent, stage of lactation at the time of mastitis. Losses are severe in primiparous cows due to clinical mastitis caused by *Staph. aureus*, *E. coli* with *Klebsiella*. However, the maximum loss of production in multiparous is caused by *Streptococcus* spp., *Staphylococcus aureus* and others pathogens [46, 47]. The loss of production is higher in multiparous cows than primiparous. Clinical mastitis occurring before peak production stage/yield causes more extensive loss as compared to rest of the lactation and loss of milk yield is persistent throughout the lactation [12, 48]. According to a study, this yield loss for multiparous could be 300-400 kg (4–6% of lactation) while 200-300 kg in primiparous

animals. The magnitude of yield loss in 30% cases of clinical mastitis reached up to 950-1050 kg per lactation. Whereas, in subclinical mastitis the losses incorporated are 80 kg/lactation (1.3%) and 120 kg/lactation (1.7%) in primiparous and multiparous respectively [49, 50].

5.2 Altered milk composition

The mastitis milk is low in fats and casein due to reduction in the synthetic capacity of secretory tissues of the udder parenchyma. The reduction in the fats up to 3-22 kg (1.5–7.5%) and casein protein contents up to 0 to 15 kg (0 to 8.5%) of the milk and higher SCC incurs the penalty to the producers in premium payment [51, 52].

5.3 Veterinary and medicinal cost

The veterinarian cost for treatment fee, travel and labor charges. On an average a handsome expenditure of \$444 in clinical mastitis case are charged. This include (128\$) directly in term of diagnostic (10\$), medicinal expenditure (\$36), discarded milk (\$25), Veterinary charges (\$41), extra labor (\$4) while death losses (\$32). The indirect costs are (\$316) which include (\$125) through future production losses and (\$182) for culling and replacement and whereas reproductive losses are (\$9). Therefore, to take an accurate decision to control the mastitis depends on understanding of economic impact of mastitis [43, 53]. Mastitis is among the main reason in cattle for the use of antibiotics and this exposure of animal to antibiotics is main reason behind the development of antibiotic resistant bacteria and antimicrobial residues in milk which are of a great public health concern [4, 7].

5.4 Discard of milk

Milk of the cow is discarded after mastitis diagnosis or while cow is being treated with antibiotics due to presence of antibiotic residues in milk during withdrawal period. The length of the withdrawal period depends on the drugs used and production system (*i.e.* conventional or organic). This discarded milk cost higher per unit than the milk not produced due to feed costs inclusions [53, 54].

5.5 Extra labor

Clinical mastitis requires extra labor for veterinary visits and medicine administration. Milking order is also changed in the clinical mastitis giving rise to less efficient milking and increasing the labors cost because hours of extra time required to manage the mastitis case [12, 53].

5.6 Subsequent disorders

The probability of subsequent clinical mastitis increases in cows once infected with mastitis. As the affected udder act as reservoir for the pathogen, the affected cows increase the spreading of mastitis in the herd. Cows having experienced one case of clinical mastitis often develop a subsequent case of clinical mastitis later in lactation. Mastitis is associated with increased risk of lameness, ketosis, displaced abomasum (LDA/RDA), and paresis and fertility problems. The economic cost of various disorders and fertility problems arise after mastitis and it is also included in the total cost of mastitis [55–57].

5.7 Culling of animal

The risk of culling and mortality rate is increased with clinical mastitis. Similar to milk loss the increased culling also augments the hidden cost. Involuntary culling is associated with replacement costs and is an important component of total mastitis cost. Economic cost also increases as cows recovered after mastitis do not reach their full production potential [9, 10, 53].

6. Review of emerging treatment options for *S. aureus* of dairy udder

6.1 NSAIDs, plant extracts, and nanoparticles as therapeutic agent

Aqib et al. [58] conducted a study to check the antibacterial of NSAIDs, plant extracts and nanoparticles against *mecA* positive *S. aureus*. Zinc oxide particles ZnO and Zn (OH) 2 were synthesized by the sorbothermal method and characterized by X-ray diffraction (XRD), calcination and scanning electron microscopy (SEM). Plant extracts were produced by the Soxhlet extraction method. The study showed that 34% (n = 200) of subclinical samples obtained from *Staphylococcus aureus* milk were significantly ($p < 0.05$) associated with suspicious risk factors and pathogens. Antibacterial studies have shown that *Staphylococcus aureus* is 55, 42, 41 and 41% resistant to oxacillin, siroxacin, streptomycin and enoxacin, respectively. Amoxicillin showed higher zone of inhibition increase at 100 mg of *Calotropis procera* extract (31.29%), followed by 1 mg/ml (28.91%) and 10 mg/ml (21.68%) eucalyptus. The combination of amoxicillin with diclofenac, aspirin, ibuprofen and meloxicam up to 500 µg/ml increases the ZOI by 42.85, 37.32, 29.05 and 22.78%, respectively. The Fractional Inhibitory Concentration Index (FICI) shows the synergistic effects of amoxicillin with diclofenac and aspirin, as well as with ibuprofen and meloxicam. Preliminary studies of the combination of micro-particles and amoxicillin in vitro have been found synergistic. In combination with zinc oxide and zinc hydroxide, the ZOI of amoxicillin increases by 26.74% and 14.85%, respectively. NSAIDs, herbal extracts and micro-particles immediately focused on the regulatory resistance of the pathogenic *Staphylococcus aureus* to explore alternative sources of antibacterial agents.

6.2 Lysostaphin as an anti-staphylococcal therapeutic agent

Lysostaphin is a potent staphylococcus-degrading enzyme containing a peptidase that can specifically cleave the polyglycine bridge specific to the cell wall of *Staphylococcus aureus*. Lysostaphin activity is measured by its ability to lyse *Staphylococcus aureus* cells. It is influenced by enzyme concentration, pH, temperature, ion and salt concentration. *Staphylococcus aureus* is enveloped in a thick layer of peptide glycans, and lysostaphin destroys the layer of peptide glycans, causing lysis and cell death. Peptide glycans impart strength and rigidity to the cell walls of gram-positive microorganisms, grow and divide, maintain cell shape, and prevent osmotic lysis of *Staphylococcus aureus*. Recombinant lysostaphin (rLYS) is a zinc metal enzyme that hydrolyzes the glycylglycine bond of a peptide glycan to a pentaglycine bridge on the cell wall of *Staphylococcus aureus*. A rodent model was used for the treatment of mastitis. The first study of rLYS in the sand showed that the rate of reduction of udder infection was over 87%, and the activity of dissolving stones in the body had a detrimental effect on the host. Instead, it reveals that it is a traditional antibacterial agent. Efficacy of rLYS in lactating dairy cows with experimentally induced *Staphylococcus aureus* infection. At least one intra-mammary

injection of 100 mg rLYS95 in 60 ml phosphate buffered saline (PBS) cures 95% of udder infection with *Staphylococcus aureus*. The antibacterial activity of rLYS *in vitro* persisted for 72 hours, but *in vivo* most of the infected mammary glands remained in the body for 72 hours after treatment [59].

6.3 Endolysin as therapeutic agent

Staphylococcus aureus is a serious threat to human and animal health, and there is an urgent need to develop new antibacterial agents to combat this pathogen. The aim of this study was to obtain active recombinant hemolysin from a novel bacteriophage (IME-SA1) and to conduct a clinical study of its effectiveness against bovine mastitis. We have isolated phages that are toxic and specific for *Staphylococcus aureus*. The optimal infection multiplier is 0.01. Electro-microscopic examination showed that IME-SA1 belongs to the Myoviridae family with the same head (98 nm) and a long tail (200 nm). Experimental lysis experiments showed a phage incubation time of 20 minutes and a burst size of 80. If the host bacterium is in the early stages of exponential growth, the multiplicity of infection is 0.01, resulting in complete lysis of the bacterium after 9 hours. We cloned the endricin gene (804 bp) into the pET-32a bacterial expression vector and succeeded in obtaining recombinant Trx-SA1 endricin with a molecule size of about 47 kDa. Preliminary results from a milk treatment study indicated that Trx-SA1 can effectively control mild clinical mastitis caused by *Staphylococcus aureus*. Endolicin Trx-SA1 may be another strategy for the treatment of infections (including MRSA) caused by *Staphylococcus aureus* [60].

6.4 Mesenchymal stem cells (MSCs)

Although many methods are effective against bovine mastitis, they do not address the problem of udder tissue regeneration and are associated with increased antibiotic resistance worldwide. Experimentally gold in terms of the safety and efficacy of staphylococcus, given the need for alternative therapies that have a large economic impact on the disease, and reports of mesenchymal stem cell (MSC) regeneration and antibacterial effects. We evaluated this intra-mammary therapy based on color-induced allogeneic MSCs. In a safety study, heifers received a 2.5×10^7 AT-MSCs on day 1 and 10. The animals are clinically examined and blood samples were taken for testing. In efficacy studies, Holstein black-and-white cows were vaccinated with *Staphylococcus aureus*, carrier (NEG; days 4 and 10), antibiotics (ATB; days 4 and 5), or 2.5×10^7 AT-. MSC (MSC; 4th and 5th day). Cows are clinically examined daily and somatic cell count (SCC) and colony forming units (CFU) are collected from milk samples. Blood samples are collected to measure serum haptoglobin and amyloid A. Two intra-mammary injections of AT-MSC into healthy dairy animals do not cause changes in clinical or hematological parameters, and pro-inflammatory cytokines. Compared to a quarter of the ATB or NEG infected cows, a quarter of the cows in the MSC group had a similar log/ ml SCC of milk. However, compared to a quarter of NEG cows, a quarter of MSC cows have a lower log CFU/ml. Re-inoculation with 2.5×10^7 allogeneic AT-MSC in the udder does not elicit a clinical or immune response in healthy cows. In addition, anti-inflammatory treatment with MSC reduced the number of bacteria in the milk of cows with clinical *Staphylococcus aureus* mastitis compared with untreated cows. This study provides preliminary evidence for the safety and efficacy of emulsions based on allogeneic intra-mammary MSCs for the treatment of bovine mastitis [61].

6.5 Bacteriophage as therapeutic agent

The lytic effects of bacterial deposition on *Staphylococcus aureus* isolates in milk have been investigated in vitro, and their possible applications in the treatment of udder infections caused by different bacteria have been discussed. The host range of the sequenced lytic phage was determined for 92 strains of *Staphylococcus aureus*. These isolates were taken from a quarter of the forehead samples in cases of clinical and subclinical mastitis. A point test followed by plaque analysis is used to determine the range of phage hosts. Three bacterial products STA1, ST29, EB1, ST11 and EB1, ST27 were selected according to host range, reproductive properties and storage properties to prepare a phage mixture (1: 1: 1) and tested for their lytic activity against *Staphylococcus aureus* in cold sterilized raw milk. It has been found that at least two-thirds of the phage can lyse almost two-thirds of the isolate. The phage mixture can reduce the density of *Staphylococcus aureus* bacteria in cold sterilized milk and retain their regenerative capacity in raw milk. Compared to pasteurized milk, the regenerative capacity is only moderately reduced. The significant decreasing capacity of the mixture of phages in raw milk facilitated further in vivo studies [62].

6.6 *Taraxocum mongolicum* as therapeutic agent

Taraxocum mongolicum is widely used as a traditional Chinese medicine for the treatment of various inflammations and infectious diseases, as well as clinically in the treatment of mastitis. The aim of this study was to investigate the protective effect of *T. mongolicum* against *S. aureus* mastitis and its underlying mechanism. Female ICR mice were given 2.5, 5 and 10 g/kg *T. mongolicum* extract twice daily for 6 consecutive days and infected with *Staphylococcus aureus* via the teat canal to induce mastitis. Anti-inflammatory cytokines such as tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6) and interleukin-1 β (IL-1 β) levels were measured by ELISA. The activity and distribution of myeloperoxidase (MPO) was measured using a kit and immunohistochemistry. Observe histo-pathological changes in udder tissue with H&E staining. Western blotting was used to demonstrate the expression of toll like receptor 2 (TLR2), phosphorylation of related nuclear factor- κ B (NF- κ B) proteins, and mitogen-activated protein kinase (MAPK) signaling pathway. *T. mongolicum* reduces TNF- and agr, IL-6- and IL-1. Serum and udder levels of mastitis infected with *Staphylococcus aureus* reduce the activity and spread of MPO. In addition, *T. mongolicum* is effective in reducing histo-pathological damage and cell necrosis in udder tissue infected with *Staphylococcus aureus*. In addition, *T. mongolicum* suppress TLR2 expression and phosphorylation of κ B α (I κ B α), p65, p38, extracellular signal kinase 1/2 (ERK1/2), and N-terminal c-Jun kinase (JNK). This study showed that *T. mongolicum* prevents mastitis caused by *Staphylococcus aureus* infection by exerting an anti-inflammatory effect by inhibiting the TLR2-NF- κ B/MAPK signaling pathway [63].

7. Role of probiotics and prebiotics in prevention of *S. aureus* infection

As mastitis is the most dangerous and costly disease of dairy industry. The use of antibiotics leads to the development of drug resistance due to which it becomes untreatable disease. Also, the presence of antibiotic residues in milk and dairy products render it unusable for consumer. So, there is another approach for prevention and treatment of mastitis [64]. Many successful experiments have been performed in past by using bacteriocin-based products. Nisin has been used as a

commercial product for the disinfection of teats. And lacticin is used in the dry cow therapy for sealing teat canal at the time of drying off of cow [54, 65].

7.1 Probiotics

Recently, there is need to use other sources in order to reduce antibiotic administration because antibiotic administration is a major cause of lethal infections in dairy industry. Probiotics are live microorganisms which when administered in sufficient amount provides cure from diseases. The probiotics which prevent diseases are called as probiotic drugs. So, mammary probiotics are recently being used as alternatives to antibiotic for the treatment of mastitis. One of the most useful probiotics are LABs (lactic acid bacteria) which interferes with bacteria associated with mastitis, or interact with mammary epithelial cells. Many experiments were performed and claims the therapeutic and preventive effectiveness of probiotics [66]. Results evaluated by using lactic acid bacteria showed that LABs are pro-inflammatory for the mammary glands and it causes an influx of neutrophils into the milk and at drying off of animals. So, it provides protection against mastitis causing *S. aureus* and their ability to provide cure from mastitis remains to be established [67]. Probiotics interferes with the teat microbiota and prevents adherence and colonization of harmful bacteria with the teat canal. However, oral probiotics provides no cure, but intra mammary preparations can be used with caution to prevent mastitis [66].

Some strains of *Lactobacillus casei* and *weissella* produces some compounds which are active against persistence of *S. aureus* bacteria with the epithelial wall of udder tissues, and thus resisting *S. aureus* bacterial pathogenicity by producing hydrogen peroxide, competing nutritional components, changing of host immune system and its utilization. Prolong use of these probiotics and their metabolites seems to be effective alternatives for the control and prevention of mastitis [66, 68].

There are many mechanisms which explain the mode of action of probiotics.

1. The change of the composition of local bacteria and production of bacteriocins and metabolites helps in the efflux of pathogenic bacteria by competing for nutrients.
2. By increases the barriers of epithelium, either by improvement of epithelial junctions or new formation of epithelial cells and introduction of antimicrobial peptides.
3. Enhancement of general immune response against bacteria. By interacting with many cells like monocytes, macrophages, and dendritic cells and train them for innate immunity.
4. Quick actions of systemic responses, like endocrine modulations or central nervous system via signaling mediators.

Different experiments are going on to unmask the details of action mechanism of probiotics in mastitis alongside boosting up the welfare and production aspects of the animals [67, 69].

7.2 Prebiotics

Antibacterial properties of prebiotics were studied *invitro*. To investigate further efficacy against bacteria studies were conducted in lab animals and their success for treatment and to prevent against bacteria was determined by evaluating liver

enzymes (aspartate transaminase and alanine transaminase), bacterial colony count of liver and lungs, and also histological changes. In some studies, raisin was used as prebiotic. But it was less effective than others. So, prebiotics are less effective against *S. aureus* than other things [70]. Synbiotics are also tested against mastitis causing bacteria. Especially, these are more effective against *E. coli* and *listeria* but less effective against *S. aureus* which is highly resistive to the synergistic effect [66, 70].

8. Vaccination against *S. aureus* udder infection

Mastitis is an important disease of the dairy industry that affects production and has economic losses, losses are due to high medicine cost and unusable milk which goes wasted as a result lowers producers' profit. For control of this disease it is necessary to follow some recommendations like teat sanitization, use of cloth to clean udder before and after milking, antibiotic treatment of clinically ill cases, dry cow therapy and proper management and nutrition of dairy animals [71]. In addition to these, vaccination against many pathogens is recommended for prevention and elimination of disease. One of the most important pathogenic entity in mastitis etiologies is *S. aureus*. In order to improve the general health, welfare, production as well as reproductive efficiency of dairy animals, many therapeutic as well as preventive approaches has been in use with less satisfactory results [72].

Staphylococcus aureus mastitis is found in many herds of dairy cows. Due to the predominant infectivity of this organism, many herds have been able to maintain a low prevalence of IMI caused by this organism. This varies greatly between herds and geographic regions, but it has been shown that calves can be infected with this pathogen during calving [73]. This pathogen usually causes only a small fraction of cases of clinical mastitis, and subclinical infections usually become chronic and refractory to treatment. The ability of this pathogen to establish a long lasting IMI varies from strain to strain. However, many toxic factors increase the viability of microorganisms in the host tissue. For longer periods of infection, fibrin deposits and abscess formation further reduce the effectiveness of the immune response. The ability of phagocytic cells to survive intracellularly affects humoral immunity and drug therapy. In addition, for example, infection with *Staphylococcus aureus*. It rarely elicits a significant innate immune response compared to *E. coli*. This avoids an acute immune response that could compromise the presence of infected tissue [74]. An effective vaccine against this pathogen must overcome some major hurdles. [1] Conservative and universal antigens are required for large variation in strains. [2] Toxic factors of "immunity", especially cell survival and the ability to not be exposed to antibodies. [3] Difficulty in assessing the effect of vaccines on reducing infections and the deleterious clinical effects of actual IMI status. The last point reflects the nature of *Staphylococcus aureus* IMI. It can be regularly excreted by bacteria in milk from infected glands. Due to L-type transformation (no cell wall mutations), *Staphylococcus aureus* can relapse in milk up to 80% of the quarter within 28 days after treatment with careful continuous sampling. IMI One or two samples are less sensitive and can correctly identify negative quarters [75].

Its need of time to control *S. aureus* for profitable business of dairy industry and for comfort of consumers with good quality milk and dairy products. In the past years, much progress was made by the researchers but in spite the use of different strategies to control mastitis, *S. aureus* is still a problem. In the dairy industry, anti-staphylococcus vaccines give different results depending upon types of immunization, route of administration, adjuvant used and involvement of some other factors [76]. Considerable effort, encompassing numerous antigens, virulence factors, and bacterial strains, has been made to develop an efficacious and practical *S. aureus* vaccine.

8.1 Vaccines available in market

Many types of vaccines are in use like commercial and herd specific (autogenous) vaccines. The purpose of vaccines is to protect new infections and to stimulate cows' immune system which may provide protection against clinical mastitis [71, 77]. Vaccination may result in the increased rate of antibodies in blood circulation against *S. aureus* pathogens which decreased bacterial growth rate after entering into the udder. The resulting increased immunity may decrease pathogen damage to milk producing tissues, decreased inflammation, and enhance tissue repair. Commercial preparations of vaccine against mastitis caused by *S. aureus* are available in the market [54]. Currently there are only 2 commercially available vaccines are in use for bovine mastitis control. Lysigin® is available in the United States and Starvac® (hipra) is available in Europe and Canada. Many others are in trials and local practices with no wide range application [6].

8.1.1 Lysigin®

Bacteria containing lysed polyvalent phage-type cultures (including several types of capsular sera) are commercially available in the United States (Lysigin; Boehringer Ingelheim, Ridgefield, CT, USA). This product was derived from a Louisiana study conducted twice every 6 months at 2-week intervals for coagulase-negative staphylococcus (CNS) and *Staphylococcus aureus* calves with decreased IMI. However, the problem that arose was that infection studies showed that this bacteriocin did not prevent IMI, did not increase IMI clearance, and did not affect SCC or post-exposure lactation. The clinical score in heifers treated with Lysigin improved and the clinical course of mastitis was short. Immunization with Lysigin increased the level of bovine serum against *Staphylococcus aureus* IgG1, but did not affect the concentration of IgG1, IgG2 or IgM in milk [75].

Lysigin® is a multivalent vaccine which is prepared by using the mastitis causing strains of *S. aureus*, disintegrated into smaller particles. Early studies showed that this vaccine reduces the risk of new infections, lowers somatic cell count and thus lowers clinical mastitis effects. It is evident from experimental studies that by following a proper vaccination schedule early in life of heifer staphylococcal mastitis can be avoided. Moreover, in some recent studies animals in which this vaccine was administered showed clinical symptoms of mastitis. But these animals recovered earlier than non-vaccinated animals; also, there was no difference in somatic cell count and *anti-S. aureus* antibodies. So, this vaccine failed to provide sufficient antibodies in milk to help leukocytes in the elimination of *S. aureus* bacteria from mammary glands. But Lysigin® vaccinated animals have a higher cure rate as compared to other animals [6, 78].

8.1.2 Starvac®

It's a multivalent vaccine which is mixture of inactivated *E. coli* and inactivated *S. aureus* which shows SAAC (slime associated antigenic complex). This preparation helps reduce clinical mastitis cases to some extent that are caused by *S. aureus* and *E. coli* bacteria. This vaccine increases antibodies but does not provide complete protection from mastitis, but decreases intramammary infections and also decreases rate of transfer of infections [79, 80].

8.1.3 Other formulations/approaches

After experimental infection, it was found that different formulations of bacterial drugs that kill whole cells can reduce the number of infections and a quarter of SCC, but this effect was only reported 13 days after infection. Subsequent field reports of two doses at the same time, lower doses in cattle and additional doses during the subsequent lactation period may produce higher antibodies against *Staphylococcus aureus*. Researchers also report that vaccinated animals consume an average of 0.5 kg of milk per day and have lower SCC levels. In this study, Freund's incomplete adjuvant was used as part of the first biphasic administration. This adjuvant is known to cause significant injection site reactions and is not commonly used in commercial products. More interesting developments from the same research group have identified targets for RNAIII-activated protein (TRAP), a highly conserved membrane protein in many *Staphylococcus* species, including *Staphylococcus aureus*. This antigen can become a specific and universal vaccine against *staphylococcus* [81]. *Staphylococcus aureus* produces adhesin, a pathogenic factor that promotes attachment of host tissues and subsequent attachment between bacterial cells, creating a biofilm that can resist feeding. Surface polysaccharides are an important component of staphylococcal biofilm, and strains expressing high levels of extracellular polysaccharides (surface-associated antigenic complex [SAAC]) have been isolated [82]. A commercial formulation combining SAAC *Staphylococcus aureus* and *E. coli* has been approved by the European Union. Clinical reports have shown that this product can improve udder health by reducing re-infection and SCC in vaccinated animals. The use of vaccines against *Staphylococcus aureus* may be restricted in many dairy farms, especially herds with low IMI prevalence, such as herds with SCC <200,000 cells/ml. Thus, *Staphylococcus aureus* bacteriosin cannot significantly influence the successful control of infectious mastitis through the use of correct milking techniques and milking machine maintenance. Conversely, people who have been vaccinated with the right treatment can experience disappointing results. As previously mentioned, this varies greatly between herds and geographic areas. If the herd has *Staphylococcus aureus*, bacteriosin can also reduce the shedding of bacteria in the milk of infected animals. Researchers have administered *Staphylococcus aureus* bacteriosin to improve antibacterial treatment, but the results are mixed [83].

8.2 Autogenous vaccine against *S. aureus* mastitis

These vaccines are the preparations having specific strains of bacteria obtained from mastitis suffered by animals and used to immunize the herd for protection against further new udder infections with the same strain of bacteria. There are evidences which shows that the use of autogenous *S. aureus* vaccines enhances antibody titer in vaccinated animals as compared to non-vaccinated herd and reduce the risk of both clinical and sub-clinical mastitis [71]. Some studies also show that autogenous vaccines provide almost 70% protection from infection and provide protection from clinically ill mastitis cases challenged with *S. aureus* [80].

Early studies suggest that vaccines for *S. aureus* will increase cure rate and lower SCC but in actuality, it does not work against adult cows. Experimental success was also seen with commercial *S. aureus* vaccine Lysigin® in the young dairy animals. When serum samples from vaccinated animals were checked they showed higher antibody titer as compared to non-vaccinated animals to combat against *S. aureus* infections [71]. So experimental and commercial preparations of *S. aureus* vaccine

provide protection against mastitis. Efficacy of these preparations against *S. aureus* ranges between 44%–66% and this strategy for prevention of *S. aureus* in the future, some new antigens and adjuvants are added to the vaccine preparations to enhance their effectiveness [72, 84].

8.3 Vaccine response in vaccinated dairy animals

Staphylococcus aureus is a predominant organism causing mastitis in different species. So, different experiments were conducted in different animal species to determine vaccine efficacy. The production and implementation of *S. aureus* vaccine in milk animals has a great impact towards public health. Inactivated vaccine was prepared and checked by using different adjuvants against *S. aureus* [85].

She camel having sub-clinical mastitis, vaccinal isolates were taken from her having alpha and beta hemolysin toxin, also some were multidrug resistant. Inactivated alum precipitated *S. aureus* vaccine (APSV) and oil adjuvant *S. aureus* vaccine (OASV) were prepared after confirming its antigenicity in rabbits. Experiments showed that APSV and OASV were safe, effective and expressed immunogenic responses in experimental rabbits [86, 87].

S. aureus is a major cause of mastitis in dairy cows causing mild to severe and chronic infections having drastic effects on cow's wellbeing, lifespan and milk production. Irrespective of years of research on mastitis issues still there is no production of an effective vaccine against *S. aureus* mastitis. Experimental studies showed that it's possible to vaccinate *S. aureus* naïve cattle and also this experimental immunization leads to humoral immune response which is different from response that occurs after natural exposure [79, 88].

Experiments are still in progress for the use of vaccine against *S. aureus* mastitis in small ruminants. Still, there is gap in using mastitis vaccine for prevention of *S. aureus* mastitis which is a major issue in dairy industry and causes huge economic losses every year. Perhaps there might be bright future for farmers because trials of mastitis vaccine in lab animals are showing satisfactory results, which is a hope [43, 50].

8.4 Vaccine success rate

Mastitis is one of the most dangerous disease of dairy industry. Vaccination and other managemental practices are the tools to prevent mastitis caused by contagious as well as environmental pathogens. The success rate of immunization depends upon type of vaccine, adjuvant used and route of administration of vaccination regardless of type of vaccine, only vaccine is not enough in the large herds with high mastitis cases. For achieving success, it is necessary to use up to date managemental practices along with vaccine and culling of chronically ill cases to reduce intra mammary infections [50, 89].

Experiments conducted from last 15 decades show that experimental *S. aureus* vaccines as well as commercial vaccines reduce new infections in dairy heifers. *S. aureus* vaccine was prepared by focusing on two major components of *S. aureus* (pseudo-capsules and alpha toxins). 2 and 4 weeks before calving heifers were given injections in the supra-mammary lymph node of mammary glands. Injections were given subcutaneously. After calving these heifers were challenged with *S. aureus* infections. These heifers showed 46% reduction in *S. aureus* infections as compared with control group of animals. There was almost 70% success rate from infection in vaccinated animals and less than 10% in non-vaccinated animals. Clinical signs of mastitis were also mild in vaccinated herds compared to control group of animals [6, 72].

9. Conclusion

Staphylococcus aureus is a major mastitis causing pathogen which is contagious in nature and persist in the mammary epithelial cell for long period of time and cause further infections. About 74% quarter prevalence of *S. aureus* in bovine udder with overall prevalence exceeding 61% in dairy animals. Cure rate in *S. aureus* mastitis is merely 25–50% during the lactation. A wide array of genotypic variations has been observed with great genetic diversity in the isolates of bovine as well as caprine origin. 17 different pulsotypes of dairy originated *S. aureus* have been reported with 24 virulence coding genes for leukocidins (lukED/lukM), pyrogenic toxin superantigen (PTS Ag), haemolysins (hla-hlg), toxic-shock syndrome toxin (tst), enterotoxins (sea-seo, seu), exfoliative toxins (eta, etb), and genes for methicillin (mecA) and penicillin (blaZ) resistance. The magnitude of yield loss in 30% cases of clinical mastitis reached up to 950-1050 kg per lactation. Attainment of refuge inside the macrophages and neutrophils is a major cause of *S. aureus* mastitis persistence. The antimicrobials cannot penetrate these structures to reach the mastitis causing organisms. This limits the use of antimicrobials to secondary importance in relation to immediate need of supportive treatment. Mammary probiotics are recently being used as alternatives to antibiotic for the treatment of mastitis. One of the most useful probiotics are lactic acid bacteria which interferes with bacteria associated with mastitis, or interact with mammary epithelial cells. Antibacterial properties of prebiotics are also studied *invitro*. Literature showed anti- *staphylococcus* vaccines with different results depending upon types of immunization, route of administration, adjuvant used and involvement of some other factors. Many types of vaccines are in use like commercial and herd specific vaccines. Commercial vaccines against mastitis caused by *S. aureus* are available in the local markets with variable efficacy around the globe. Studies conducted from last 15 decades show that experimental herd specific *S. aureus* vaccines as well as commercial vaccines reduce new infections in dairy heifers. Experiments are still in progress for the use of vaccine against *S. aureus* mastitis with optimal efficacy and reliability. Still, there is knowledge gap in using vaccines for prevention of *S. aureus* mastitis, needed to be research in focus. Perhaps, there might be bright future for farmers because of highly satisfactory trial results of mastitis vaccines in the lab animals.

IntechOpen

Author details

Amjad Islam Aqib^{1*}, Muhammad Ijaz², Muhammad Shoaib^{3,4}, Iqra Muzammil², Hafiz Iftikhar Hussain¹, Tean Zaheer⁵, Rais Ahmed¹, Iqra Sarwar⁵, Yasir Razzaq Khan¹ and Muhammad Aamir Naseer⁵

1 Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan

2 University of Veterinary and Animal Sciences, Lahore, Pakistan

3 Institute of Microbiology, University of Agriculture Faisalabad, Pakistan

4 Key Laboratory of New Animal Drug Project, Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China

5 University of Agriculture, Faisalabad, Pakistan

*Address all correspondence to: amjadwaseer@gmail.com

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Shoaib M, Rahman SU, Aqib AI, Ashfaq K, Naveed A, Kulyar MF-A, et al. Diversified Epidemiological Pattern and Antibioqram of mecA Gene in Staphylococcus aureus Isolates of Pets, Pet Owners and Environment. Pak Vet J. 2020;40(3):331-336.
- [2] Aqib A, Nighat S, Ahmed R, Sana S, Jamal M, Kulyar MF, et al. Drug Susceptibility Profile of *Staphylococcus aureus* Isolated from Mastitic Milk of Goats and Risk Factors Associated with Goat Mastitis in Pakistan. Vol. 51. Pakistan J. Zool., Vol. 51, Iss. 1, pp. 307-315 Read more at <http://researcherslinks.com/current-issues/Drug-Susceptibility-Profile-of-Staphylococcus/20/1/1880/html#KolwAq8XDDQ2YXZo.99>; 2018. 307-315 p.
- [3] A Begum H, S Uddin M, J Islam M, Nazir KHMNH, Islam M, Rahman MT. Detection of biofilm producing coagulase positive *Staphylococcus aureus* from bovine mastitis, their pigment production, hemolytic activity and antibiotic sensitivity pattern. 4(1 & 2): J. Bangladesh Soc. Agric. Sci. Technol.4(1 & 2): 97-100; 2007.
- [4] Naseer MA, Aqib AI, Ashar A, Saleem MI, Shoaib M, Kulyar MF-A, et al. Detection of Altered Pattern of Antibioqram and Biofilm Character in *Staphylococcus aureus* Isolated From Dairy Milk. Pakistan J Zool. 2020;
- [5] Basanisi MG, La Bella G, Nobili G, Franconieri I, La Salandra G. Genotyping of methicillin-resistant Staphylococcus aureus (MRSA) isolated from milk and dairy products in South Italy. Food Microbiol. 2017;62:141-146.
- [6] Côté-Gravel J, Malouin F. Symposium review: Features of Staphylococcus aureus mastitis pathogenesis that guide vaccine development strategies*. J Dairy Sci. 2019;102(5):4727-4740.
- [7] Hossain SMA. Efficacy of dry cow therapy in mastitis control strategy. MS Thesis. Department of Surgery and Obstetrics, Faculty of Veterinary ...; 2004.
- [8] Abo-EL-Sooud K. Ethnoveterinary perspectives and promising future. Int J Vet Sci Med. 2018;6(1):1-7.
- [9] Radostits OM, Gay CC, Hinchcliff KW, Constable PD. Veterinary Medicine E-Book: A textbook of the diseases of cattle, horses, sheep, pigs and goats. Elsevier Health Sciences; 2006.
- [10] van Soest FJS, Mourits MCM, Blanco-Penedo I, Duval J, Fall N, Krieger M, et al. Farm-specific failure costs of production disorders in European organic dairy herds. Prev Vet Med. 2019;168:19-29.
- [11] Jingar S, Chhokar MS, Roy A, Sharma R, Lawania P, Kumar A, et al. Economic Loss due to Clinical Mastitis in Crossbred Cows. Int J Livest Res. 2018 Jan;1.
- [12] Hagnestam-Nielsen C, Ostergaard S. Economic impact of clinical mastitis in a dairy herd assessed by stochastic simulation using different methods to model yield losses. Animal. 2009 Feb;3(2):315-328.
- [13] Petersson-Wolfe CS, Mullarky IK, Jones GM. *Staphylococcus aureus* mastitis: cause, detection, and control. 2010;
- [14] Masse E, CHAKRAVARTY S. RNA-dependent regulation of virulence in pathogenic bacteria. Front Cell Infect Microbiol. 2019;9:337.
- [15] Quinn PJ, Markey BK, Leonard FC, Hartigan P, Fanning S, Fitzpatrick Es. Veterinary microbiology and microbial disease. John Wiley & Sons; 2011.

- [16] Kashif A, McClure J-AM, Lakhundi S, Pham M, Chen S, Conly J, et al. *Staphylococcus aureus* ST398 Virulence Is Associated with Factors Carried on Prophage Φ Sa3. *Front Microbiol.* 2019;10:2219.
- [17] Algharib SA, Dawood A, Xie S. Nanoparticles for treatment of bovine *Staphylococcus aureus* mastitis. *Drug Deliv.* 2020;27(1):292-308.
- [18] Clauditz A, Resch A, Wieland K-P, Peschel A, Götz F. Staphyloxanthin plays a role in the fitness of *Staphylococcus aureus* and its ability to cope with oxidative stress. *Infect Immun.* 2006;74(8):4950-4953.
- [19] Zaatout N, Ayachi A, Kecha M. Interaction of primary mammary bovine epithelial cells with biofilm-forming staphylococci associated with subclinical bovine mastitis. *Iran J Vet Res.* 2019;20(1):27.
- [20] Zaatout N, Ayachi A, Kecha M. *Staphylococcus aureus* persistence properties associated with bovine mastitis and alternative therapeutic modalities. *J Appl Microbiol.* 2020;
- [21] Sutra L, Poutrel B. Virulence factors involved in the pathogenesis of bovine intramammary infections due to *Staphylococcus aureus*. *J Med Microbiol.* 1994;40(2):79-89.
- [22] Sears PM, Smith BS, English PB, Herer PS, Gonzalez RN. Shedding Pattern of *Staphylococcus aureus* from Bovine Intramammary Infections. *J Dairy Sci.* 1990;73(10):2785-2789.
- [23] Jørgensen HJ, Mørk T, Caugant DA, Kearns A, Rørvik LM. Genetic variation among *Staphylococcus aureus* strains from Norwegian bulk milk. *Appl Environ Microbiol.* 2005;71(12):8352-8361.
- [24] Asselstine V, Miglior F, Suárez-Vega A, Fonseca PAS, Mallard B, Karrow N, et al. Genetic mechanisms regulating the host response during mastitis. *J Dairy Sci.* 2019;102(10):9043-9059.
- [25] Filipe J, Bronzo V, Curone G, Castiglioni B, Vigo D, Smith B, et al. *Staphylococcus aureus* intra-mammary infection affects the expression pattern of IL-R8 in goat. *Comp Immunol Microbiol Infect Dis.* 2019;66:101339.
- [26] Aires-de-Sousa M, Parente CESR, Vieira-da-Motta O, Bonna ICF, Silva DA, de Lencastre H. Characterization of *Staphylococcus aureus* isolates from buffalo, bovine, ovine, and caprine milk samples collected in Rio de Janeiro State, Brazil. *Appl Environ Microbiol.* 04/20. 2007;73(12):3845-9.
- [27] Sakwinska O, Giddey M, Moreillon M, Morisset D, Waldvogel A, Moreillon P. *Staphylococcus aureus* host range and human-bovine host shift. *Appl Environ Microbiol.* 2011;77(17):5908-5915.
- [28] Haran KP, Godden SM, Boxrud D, Jawahir S, Bender JB, Sreevatsan S. Prevalence and Characterization of *Staphylococcus aureus*, Including Methicillin-Resistant *S. aureus*. *J Clin Microbiol.* 2012 Mar;50(3):688 LP – 695.
- [29] Akpaka PE, Roberts R, Monecke S. Molecular characterization of antimicrobial resistance genes against *Staphylococcus aureus* isolates from Trinidad and Tobago. *J Infect Public Heal.* 2016/06/23. 2017;10(3):316-23.
- [30] Dodémont M, Argudín MA, Willekens J, Vanderhelst E, Pierard D, Miendje Deyi VY, et al. Emergence of livestock-associated MRSA isolated from cystic fibrosis patients: Result of a Belgian national survey. *J Cyst Fibros.* 2019;18(1):86-93.
- [31] Zehra A, Gulzar M, Singh R, Kaur S, Gill JPS. Prevalence, multidrug

resistance and molecular typing of methicillin-resistant *Staphylococcus aureus* (MRSA) in retail meat from Punjab, India. *J Glob Antimicrob Resist*. 2019;16:152-158.

[32] Kapur V, Sisco WM, Greer RS, Whittam TS, Musser JM. Molecular population genetic analysis of *Staphylococcus aureus* recovered from cows. *J Clin Microbiol*. 1995;33(2):376.

[33] Fox LK, Zadoks RN, Gaskins CT. Biofilm production by *Staphylococcus aureus* associated with intramammary infection. *Vet Microbiol*. 2005;107(3):295-299.

[34] Vaughn JM, Abdi RD, Gillespie BE, Kerro Dego O. Genetic diversity and virulence characteristics of *Staphylococcus aureus* isolates from cases of bovine mastitis. *Microb Pathog*. 2020;144:104171.

[35] Zayda MG, Masuda Y, Hammad AM, Honjoh K, Elbagory AM, Miyamoto T. Molecular characterisation of methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) *Staphylococcus aureus* isolated from bovine subclinical mastitis and Egyptian raw milk cheese. *Int Dairy J*. 2020;104:104646.

[36] Azzi O, Lai F, Tennah S, Menoueri MN, Achek R, Azara E, et al. Spa-typing and antimicrobial susceptibility of *Staphylococcus aureus* isolated from clinical sheep mastitis in Medea province, Algeria. *Small Rumin Res*. 2020;106:168.

[37] Wang W, Lin X, Jiang T, Peng Z, Xu J, Yi L, et al. Prevalence and Characterization of *Staphylococcus aureus* Cultured From Raw Milk Taken From Dairy Cows With Mastitis in Beijing, China. *Front Microbiol*. 2018;9:1123.

[38] Melchior MB, Van Duinkerken E, Mevius DJ, Nielen M, Fink-Gremmels J.

Genotyping and biofilm formation of *Staphylococcus aureus* isolates: Evidence for lack of penicillin-resistance in Agr-type II strains. In: *Mastitis Control: From Science to Practice*. Elsevier; 2008. p. 308.

[39] Cucarella C, Tormo MA, Ubeda C, Trotonda MP, Monzón M, Peris C, et al. Role of biofilm-associated protein bap in the pathogenesis of bovine *Staphylococcus aureus*. *Infect Immun*. 2004;72(4):2177-2185.

[40] Haveri M, Roslöf A, Rantala L, Pyörälä S. Virulence genes of bovine *Staphylococcus aureus* from persistent and nonpersistent intramammary infections with different clinical characteristics. *J Appl Microbiol*. 2007 Oct;103(4):993-1000.

[41] Angelidis AS, Komodromos D, Giannakou R, Arsenos G, Gelasakis AI, Kyritsi M, et al. Isolation and characterization of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* (MRSA) from milk of dairy goats under low-input farm management in Greece. *Vet Microbiol*. 2020;247:108749.

[42] Ibrahim N. Review on Mastitis and Its Economic Effect. *Can J Sci Res*. 2017 Jan;6:13-22.

[43] Rollin E, Dhuyvetter KC, Overton MW. The cost of clinical mastitis in the first 30 days of lactation: An economic modeling tool. *Prev Vet Med*. 2015 Dec;122(3):257-264.

[44] Dego OK. Current Status of Antimicrobial Resistance and Prospect for New Vaccines against Major Bacterial Bovine Mastitis Pathogens. In: *Animal Reproduction in Veterinary Medicine*. IntechOpen; 2020.

[45] Klaas IC, Zadoks RN. An update on environmental mastitis: Challenging perceptions. *Transbound Emerg Dis*. 2018 May;65(S1):166-185.

- [46] Mbindyo CM, Gitao GC, Mulei CM. Prevalence, Etiology, and Risk Factors of Mastitis in Dairy Cattle in Embu and Kajiado Counties, Kenya. *Vet Med Int.* 2020 Aug;2020:8831172.
- [47] Tarazona-Manrique LE, Villate-Hernández JR, Andrade-Becerra RJ. Bacterial and fungal infectious etiology causing mastitis in dairy cows in the highlands of Boyacá (Colombia). Vol. 66, *Revista de la Facultad de Medicina Veterinaria y de Zootecnia. scieloco*; 2019. p. 208-18.
- [48] Breen JE, Green MJ, Bradley AJ. Quarter and cow risk factors associated with the occurrence of clinical mastitis in dairy cows in the United Kingdom. *J Dairy Sci.* 2009;92(6):2551-2561.
- [49] Carrillo-Casas EM, Miranda-Morales RE. Bovine mastitis pathogens: prevalence and effects on somatic cell count. In: *Milk Production-An Up-to-Date Overview of Animal Nutrition, Management and Health.* IntechOpen; 2012.
- [50] Contreras Bravo G, Rodríguez J. Mastitis: Comparative Etiology and Epidemiology. *J Mammary Gland Biol Neoplasia.* 2011 Sep;16:339-356.
- [51] Petrovski KR, Buneski G, Trajcev M. A review of the factors affecting the costs of bovine mastitis. *J S Afr Vet Assoc.* 2006;77(2):52-60.
- [52] Janzen JJ. Economic losses resulting from mastitis. A review. *J Dairy Sci.* 1970;53(9):1151-1160.
- [53] Seegers H, Fourichon C, Beaudeau F. Production effects related to mastitis and mastitis economics in dairy cattle herds. *Vet Res.* 2003 Sep;34:475-491.
- [54] Hogeveen H, Huijps K, Lam T, De Vlieghe S, Fox LK, Piepers S, et al. Economic aspects of mastitis: New developments. *N Z Vet J.* 2011;59(1):357-372.
- [55] Weller JI, Ezra E, van Straten M. Genetic and environmental analysis of diseases with major economic impact in Israeli Holsteins. *J Dairy Sci.* 2019;102(11):10030-10038.
- [56] Richert RM, Cicconi KM, Gamroth MJ, Schukken YH, Stiglbauer KE, Ruegg PL. Risk factors for clinical mastitis, ketosis, and pneumonia in dairy cattle on organic and small conventional farms in the United States. *J Dairy Sci.* 2013;96(7):4269-4285.
- [57] Esposito G, Irons PC, Webb EC, Chapwanya A. Interactions between negative energy balance, metabolic diseases, uterine health and immune response in transition dairy cows. *Anim Reprod Sci.* 2014;144(3):60-71.
- [58] Aqib AI, Saqib M, Khan SR, Ahmad T, Shah SA, Naseer MA, et al. Non-steroidal anti-inflammatory drugs, plant extracts, and characterized microparticles to modulate antimicrobial resistance of epidemic *mecA* positive *S. aureus* of dairy origin. *Applied Nanoscience.*:1-1
- [59] Cardoso CV, Barbosa EV, Liberal MHT, das Chagas EF. Transgenic technology: the strategy for the control and prevention of bovine staphylococcal mastitis? *Biotechnol Res Innov.* 2019;3(2):291-297.
- [60] Fan J, Zeng Z, Mai K, Yang Y, Feng J, Bai Y, et al. Preliminary treatment of bovine mastitis caused by *Staphylococcus aureus*, with *trx-SA1*, recombinant endolysin of *S. aureus* bacteriophage *IME-SA1*. *Vet Microbiol.* 2016;191:65-71.
- [61] Peralta OA, Carrasco C, Vieytes C, Tamayo MJ, Muñoz I, Sepulveda S, et al. Safety and efficacy of a mesenchymal stem cell intramammary therapy in

dairy cows with experimentally induced Staphylococcus aureus clinical mastitis. Sci Rep. 2020;10(1):1-12.

[62] Titze I, Lehnher T, Lehnher H, Krömker V. Efficacy of bacteriophages against Staphylococcus aureus isolates from bovine mastitis. Pharmaceuticals. 2020;13(3):35.

[63] Ge B, Zhao P, Li H, Sang R, Wang M, Zhou H, et al. Taraxacum mongolicum protects against Staphylococcus aureus-infected mastitis by exerting anti-inflammatory role via TLR2-NF- κ B/MAPKs pathways in mice. J Ethnopharmacol [Internet]. 2020;113595. Available from: <http://www.sciencedirect.com/science/article/pii/S0378874120334838>

[64] Abdurahman OAS. Udder health and milk quality among camels in the Errer valley of eastern Ethiopia. Livest Res Rural Dev. 2006 Jan;18.

[65] Zadoks RN, Middleton JR, McDougall S, Katholm J, Schukken YH. Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans. J Mammary Gland Biol Neoplasia. 2011;

[66] Rainard P, Foucras G. A Critical Appraisal of Probiotics for Mastitis Control . Vol. 5, Frontiers in Veterinary Science . 2018. p. 251.

[67] Soleimani N, Kermanshahi R, Yakhchali B, Sattari T. Antagonistic activity of probiotic lactobacilli against Staphylococcus aureus isolated from bovine mastitis. African J Microbiol Res. 2010 Nov;420:2169-2173.

[68] Rainard P, Riollot C. Innate immunity of the bovine mammary gland. Vet Res. 2006 May;37(3):369-400.

[69] Wilson DJ, Grohn YT, Bennett GJ, González RN, Schukken YH, Spatz J. Comparison of J5 Vaccinates and Controls for Incidence, Etiologic Agent,

Clinical Severity, and Survival in the Herd Following Naturally Occurring Cases of Clinical Mastitis. J Dairy Sci. 2007;90(9):4282-4288.

[70] Gadde U, Kim WH, Oh ST, Lillehoj HS. Alternatives to antibiotics for maximizing growth performance and feed efficiency in poultry: A review. Anim Heal Res Rev. 2017;18(1):26-45.

[71] Landin H, Jansson Mörk M, Larsson M, Waller K. Vaccination against Staphylococcus aureus mastitis in two Swedish dairy herds. Acta Vet Scand. 2015 Nov;57:81.

[72] Pereira UP, Oliveira DGS, Mesquita LR, Costa GM, Pereira LJ. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol. 2011 Mar;148(2-4):117-124.

[73] Borm AA, Fox LK, Leslie KE, Hogan JS, Andrew SM, Moyes KM, et al. Effects of prepartum intramammary antibiotic therapy on udder health, milk production, and reproductive performance in dairy heifers. J Dairy Sci. 2006;89(6):2090-2098.

[74] Petzl W, Zerbe H, Günther J, Yang W, Seyfert H-M, Nürnberg G, et al. Escherichia coli, but not Staphylococcus aureus triggers an early increased expression of factors contributing to the innate immune defense in the udder of the cow. Vet Res. 2008;39(2):1-23.

[75] Middleton JR, Luby CD, Viera L, Tyler JW, Casteel S. Influence of Staphylococcus aureus intramammary infection on serum copper, zinc, and iron concentrations. J Dairy Sci. 2004;87(4):976-979.

[76] Scali F, Camussone C, Calvinho L, Cipolla M, Zecconi A. Which are important targets in development of S.aureus mastitis vaccine? Res Vet Sci. 2015 Mar;100.

- [77] Vasileiou NGC, Cripps PJ, Ioannidi KS, Katsafadou AI, Chatzopoulos DC, Barbagianni MS, et al. Experimental study for evaluation of the efficacy of a biofilm-embedded bacteria-based vaccine against *Staphylococcus chromogenes*-associated mastitis in sheep. *Vet Microbiol.* 2019;239:108480.
- [78] Middleton JR, Ma J, Rinehart CL, Taylor VN, Luby CD, Steevens BJ. Efficacy of different Lysigin (TM) formulations in the prevention of *Staphylococcus aureus* intramammary infection in dairy heifers. *J Dairy Res.* 2006;73(1):10.
- [79] Niedziela DA, Murphy MP, Grant J, Keane OM, Leonard FC. Clinical presentation and immune characteristics in first-lactation Holstein-Friesian cows following intramammary infection with genotypically distinct *Staphylococcus aureus* strains. *J Dairy Sci.* 2020;
- [80] Cheng WN. Bovine mastitis: risk factors, therapeutic strategies, and alternative treatments. *Asian-Australasian J Anim Sci.* 2020 May;
- [81] Leitner G, Krifucks O, Kiran MD, Balaban N. Vaccine development for the prevention of staphylococcal mastitis in dairy cows. *Vet Immunol Immunopathol.* 2011;142(1-2):25-35.
- [82] Prenafeta A, March R, Foix A, Casals I, Costa L. Study of the humoral immunological response after vaccination with a *Staphylococcus aureus* biofilm-embedded bacterin in dairy cows: possible role of the exopolysaccharide specific antibody production in the protection from *Staphylococcus aureus* induced mastitis. *Vet Immunol Immunopathol.* 2010;134(3-4):208-217.
- [83] Erskine RJ. Vaccination strategies for mastitis. *Vet Clin North Am Food Anim Pract.* 2012;28(2):257-270.
- [84] Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. *Trends Immunol.* 2009 Jan;30(1):23-32.
- [85] Tollersrud T, Kenny K, Caugant D, Lund A. Characterisation of isolates of *Staphylococcus aureus* from acute, chronic and subclinical mastitis in cows in Norway. *APMIS.* 2000 Oct;108:565-572.
- [86] Ali M, Avais M, Ijaz M, Chaudhary M, Hussain R, Aqib A, et al. Epidemiology of Subclinical Mastitis in Dromedary Camels (*Camelus dromedarius*) of Two Distinct Agro-Ecological Zones of Pakistan. *Pak J Zool.* 2019 Feb;51.
- [87] Aqib AI, Ijaz M, Farooqi SH, Ahmed R, Shoaib M, Ali MM, et al. Emerging discrepancies in conventional and molecular epidemiology of methicillin resistant *Staphylococcus aureus* isolated from bovine milk. *Microb Pathog.* 2018;116:38-43.
- [88] Shittu A, Abdullahi J, Jibril A, Mohammed AA, Fasina FO. Sub-clinical mastitis and associated risk factors on lactating cows in the Savannah Region of Nigeria. *BMC Vet Res.* 2012;8(1):134.
- [89] Dodd FH. Mastitis--progress on control. *J Dairy Sci.* 1983 Aug;66(8):1773-1780.